Skip to main content

Anne E. O’Donnell, MD

Anne E. O’Donnell, MD

The Nehemiah and Naomi Cohen Chair in Pulmonary Disease Research
Professor of Medicine
Interim Chair, Department of Medicine
Chief, Division of Pulmonary, Critical Care and Sleep Medicine
Georgetown University Medical Center

The Nehemiah and Naomi Cohen Chair in Pulmonary Disease Research
Professor of Medicine
Interim Chair, Department of Medicine
Chief, Division of Pulmonary, Critical Care and Sleep Medicine
Georgetown University Medical Center

Are there patients who, by virtue of having adverse prognostic features for NCFBE, you would consider highly amenable candidates for brensocatib therapy? How should this novel treatment fit into our clinical care model?

Are there patients who, by virtue of having adverse prognostic features for NCFBE, you would consider highly amenable candidates for brensocatib therapy? How should this novel treatment fit into our clinical care model?

Anne E. O’Donnell, MD

How does adding brensocatib to the multimodal NCFBE toolkit mark a meaningful clinical advance, and based on WILLOW, ASPEN, and the FDA label, what role might this inflammation-reducing DPP-1 inhibitor play in managing the disease?

How does adding brensocatib to the multimodal NCFBE toolkit mark a meaningful clinical advance, and based on WILLOW, ASPEN, and the FDA label, what role might this inflammation-reducing DPP-1 inhibitor play in managing the disease?

Anne E. O’Donnell, MD

Once you commit a patient to brensocatib, how do you follow therapeutic progress? Do you use biomarkers? Other monitoring strategies?

Once you commit a patient to brensocatib, how do you follow therapeutic progress? Do you use biomarkers? Other monitoring strategies?

The Nehemiah and Naomi Cohen Chair in Pulmonary Disease ResearchProfessor of MedicineInterim Chair, Department of MedicineChief, Division of Pulmonary, Critical Care and Sleep MedicineGeorgetown University Medical Center

Anne E. O’Donnell, MD

Once you start a patient on brensocatib, what should you see in a patient who is responding well to this therapy? And how long does it take to confirm drug effectiveness?

Once you start a patient on brensocatib, what should you see in a patient who is responding well to this therapy? And how long does it take to confirm drug effectiveness?

Anne E. O’Donnell, MD

Professor O’Donnell, can you kindly introduce yourself and your role at Georgetown University Medical Center, and share with us your interest in identifying new, approved therapeutic strategies for NCFBE?

Professor O’Donnell, can you kindly introduce yourself and your role at Georgetown University Medical Center, and share with us your interest in identifying new, approved therapeutic strategies for NCFBE?

Anne E. O’Donnell, MD

What does the current NCFBE toolkit include, what are its key strengths and weaknesses—especially regarding the inflammatory vortex—and what unmet needs remain to achieve better clinical outcomes?

What does the current NCFBE toolkit include, what are its key strengths and weaknesses—especially regarding the inflammatory vortex—and what unmet needs remain to achieve better clinical outcomes?

Anne E. O’Donnell, MD

What is the data- and science-driven rationale for focusing on neutrophil-mediated inflammation as a pathobiological target—in addition, let’s say to infectious pathogens—for managing NCFBE?

What is the data- and science-driven rationale for focusing on neutrophil-mediated inflammation as a pathobiological target—in addition, let’s say to infectious pathogens—for managing NCFBE?

Anne E. O’Donnell, MD

What, in your assessment, were the most significant primary and secondary end points achieved in the ASPEN trial evaluating the safety and efficacy of brensocatib in NCFBE?

What, in your assessment, were the most significant primary and secondary end points achieved in the ASPEN trial evaluating the safety and efficacy of brensocatib in NCFBE?

Anne E. O’Donnell, MD

With FDA approval of brensocatib for bronchiectasis, which clinical features help identify NCFBE patients best suited for this inflammation-targeting therapy, based on disease pattern, exacerbation history, and underlying biology?

With FDA approval of brensocatib for bronchiectasis, which clinical features help identify NCFBE patients best suited for this inflammation-targeting therapy, based on disease pattern, exacerbation history, and underlying biology?

Anne E. O’Donnell, MD

With new NCFBE therapies like brensocatib targeting neutrophil-driven inflammation, how have the WILLOW and ASPEN trials advanced understanding of its benefits and helped move clinical care forward?

With new NCFBE therapies like brensocatib targeting neutrophil-driven inflammation, how have the WILLOW and ASPEN trials advanced understanding of its benefits and helped move clinical care forward?

Anne E. O’Donnell, MD